Skip to content
Screener

NovoCure NVCR Cash & Equivalents

Cash & Equivalents at other companies

Boston Scientific logo
Boston ScientificBSX
$850M+146%
Medtronic logo
MedtronicMDT
$1.95B-12.1%
Nuvation Bio logo
Nuvation BioNUVB
$258.6M+4.3%
Iovance Biotherapeutics, Inc. logo
Iovance Biotherapeutics, Inc.IOVA
$110.77M-16.4%
Tango Therapeutics logo
Tango TherapeuticsTNGX
$159.97M+162%
Gyre Therapeutics, Inc. logo
Gyre Therapeutics, Inc.GYRE
$43.29M+18.6%

Other financials

Income statement

See full
Revenue$183.6M+15.6%
Gross profit$142.5M+21.4%
Operating income-$10.6M+73.3%
Net income-$15.7M+61.0%
EPS (diluted)-$0.13+63.9%

Balance sheet

See full
Total debt$37.5M-12.4%
Total equity$338.1M-3.2%
Total assets$795.2M-36.2%

Cash flow

See full
Operating cash flow$8.1M+151%
CapEx$6.9M+26.1%
Free cash flow$1.2M+106%

Valuation

See full
Market cap$1.91B+56.6%
Enterprise value$1.85B+66.6%
P/S2.7×+0.8×

Profitability

See full
Gross margin76.1%-0.3pp
Operating margin-22.1%-3.6pp
Net margin-21.2%-3.8pp
FCF margin-3.6%-1.5pp

Returns & leverage

See full
Return on equity-43.2%-4.0pp
Debt / equity0.1×0.0×
Current ratio2.9×+1.4×

Where this comes from

Reported directly by NovoCure in its filing.

Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.

The source filing: NovoCure’s 10-Q, filed July 23, 2026.

Filed
Jul 23, 2026, 6:59 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001645113-26-000062
Line itemJune 30,2026December 31, 2025
ASSETS
CURRENT ASSETS:
Cash and cash equivalents$93,701$93,548
Short-term investments346,858354,126
Restricted cash9,9179,842
Trade receivables, net99,13189,435
Receivables and prepaid expenses46,69058,669
Inventories42,22441,111

Item 1. Financial Statements

FAQ

What is NovoCure's cash & equivalents?
NovoCure (NVCR) reported cash & equivalents of $93.7M in Q2 2026.
How has NovoCure's cash & equivalents changed year-over-year?
NovoCure's cash & equivalents decreased by 37.4% year-over-year, from $149.62M to $93.7M.
What is the long-term trend for NovoCure's cash & equivalents?
Over 5 years (2020 to 2025), NovoCure's cash & equivalents has grown at a -16.8% compound annual growth rate (CAGR), from $234.67M to $93.55M.
What does cash & equivalents mean?
Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.

Ask your AI about NovoCure's cash & equivalents.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude